# Apothecon Group 宣布 Shyamakant Giri 自 2026 年 5 月 11 日起擔任新任執行長。

*biotech, business · news · 2026-05-15 · Devdiscourse*

## Key points

- Shyamakant Giri 將於 2026 年 5 月 11 日成為 Apothecon Group 執行長。
- Giri 先前曾任職於 Gland Pharma Limited 執行長，加入 Apothecon Group 前擁有豐富經驗。
- 在 Giri 的領導下，Apothecon Group 計劃全球擴展，重點發展複雜仿製藥。
- Everstone Capital 支持 Apothecon Group，並且是高成長產業的重要投資者。

Apothecon Group has announced Shyamakant Giri as the new Chief Executive Officer, effective May 11, 2026. With a base in Vadodara, India, Giri is set to drive the company's forthcoming growth and strategic expansion phases. Supported by Everstone Capital, a key player in investment across high-growth sectors, Apothecon Group specializes in pharmaceutical and healthcare market solutions. Mr. Giri, with over 25 years in leadership roles within pharmaceuticals and healthcare, joins from Gland Pharma Limited where he was CEO. Giri expressed his enthusiasm, stating that the group's development, manufacturing, and marketing strengths in complex generic drugs provide a robust platform for further growth. The company aims to leverage his expertise in their bid to strengthen their global marketplace presence. (With inputs from agencies.)

**Companies:** Everstone Capital, Apothecon Group, Gland Pharma Limited
**Countries:** India

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3909165-shyamakant-giri-appointed-ceo-of-apothecon-group)

---

Canonical: https://newsio.io/zh-TW/n/ad6dac43-37bd-443c-97b4-61a5de20eb7e/apothecon-group-shyamakant-giri-2026-5-11-apothecon-group-everstone-capital
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works